Takashi Okada

Dr. Takashi Okada


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Human Gene Therapy
Verified
Journal Article
Closed access
TOTakashi Okada
Takashi Okada
MNMutsuko Nonaka-Sarukawa
Mutsuko Nonaka-Sarukawa
RURyosuke Uchibori
Ryosuke Uchibori
KKKazue Kinoshita
Kazue Kinoshita
HHHiromi Hayashita-Kinoh
Hiromi Hayashita-Kinoh
KOKeiya Ozawa
Keiya Ozawa
In vivo gene transduction with adeno-associated virus (AAV)-based vectors depends on laborious procedures for the production of high-titer vector stocks. Purification steps for efficient clearance of impurities such as host cell proteins and empty vector particles are required to meet end-product specifications. Therefore, the development of alternative, realistic methods to facilitate a scalable virus recovery procedure is critical to promote in vivo investigations. However, the conventional purification procedure with resin-based packed-bed chromatography suffers from a number of limitations, including variations in pressure, slow pore diffusion, and large bed volumes. Here we have employed disposable high-performance anion- and cation-exchange membrane adsorbers to effectively purify recombinant viruses. As a result of isoelectric focusing analysis, the isoelectric point of empty particles was found to be significantly higher than that of packaged virions. Therefore, AAV vector purification with the membrane adsorbers was successful and allowed higher levels of gene transfer in vivo without remarkable signs of toxicity or inflammation. Electron microscopy of the AAV vector stocks obtained revealed highly purified virions with as few as 0.8% empty particles. Furthermore, the membrane adsorbers enabled recovery of AAV vectors in the transduced culture supernatant. Also, the ion-exchange enrichment of retroviral vectors bearing the amphotropic envelope was successful. This rapid and scalable viral purification protocol using disposable membrane adsorbers is particularly promising for in vivo experimentation and clinical investigations.

1 January 2009 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
SOSachiko Ohshima
Sachiko Ohshima
JSJin-Hong Shin
Jin-Hong Shin
KYKatsutoshi Yuasa
Katsutoshi Yuasa
ANAkiyo Nishiyama
Akiyo Nishiyama
JKJunichi Kira
Junichi Kira
STShin'ichi Takeda
Shin'ichi Takeda
Recombinant adeno-associated virus (rAAV)-mediated gene transfer is an attractive approach to the treatment of Duchenne muscular dystrophy (DMD). We investigated the muscle transduction profiles and immune responses associated with the administration of rAAV2 and rAAV8 in normal and canine X-linked muscular dystrophy in Japan (CXMDJ) dogs. rAAV2 or rAAV8 encoding the lacZ gene was injected into the skeletal muscles of normal dogs. Two weeks after the injection, we detected a larger number of β-galactosidase-positive fibers in rAAV8-transduced canine skeletal muscle than in rAAV2-transduced muscle. Although immunohistochemical analysis using anti-CD4 and anti-CD8 antibodies revealed less T-cell response to rAAV8 than to rAAV2, β-galactosidase expression in rAAV8-injected muscle lasted for <4 weeks with intramuscular transduction. Canine bone marrow-derived dendritic cells (DCs) were activated by both rAAV2 and rAAV8, implying that innate immunity might be involved in both cases. Intravenous administration of rAAV8-lacZ into the hind limb in normal dogs and rAAV8-microdystrophin into the hind limb in CXMDJ dogs resulted in improved transgene expression in the skeletal muscles lasting over a period of 8 weeks, but with a declining trend. The limb perfusion transduction protocol with adequate immune modulation would further enhance the rAAV8-mediated transduction strategy and lead to therapeutic benefits in DMD gene therapy.

1 January 2012 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
YNYuko Nitahara-Kasahara
Yuko Nitahara-Kasahara
HHHiromi Hayashita-Kinoh
Hiromi Hayashita-Kinoh
SOSachiko Ohshima-Hosoyama
Sachiko Ohshima-Hosoyama
HOHironori Okada
Hironori Okada
MWMichiko Wada-Maeda
Michiko Wada-Maeda
STShin'IChi Takeda
Shin'IChi Takeda
Duchenne muscular dystrophy (DMD) is an incurable genetic disease with early mortality. Multipotent mesenchymal stromal cells (MSCs) are of interest because of their ability to differentiate to form myogenic cells in situ. In the present study, methods were developed to expand cultures of MSCs and to promote the myogenic differentiation of these cells, which were then used in a new approach for the treatment of DMD. MSC cultures enriched in CD271+ cells grew better than CD271-depleted cultures. The transduction of CD271+ MSCs with MyoD caused myogenic differentiation in vitro and the formation of myotubes expressing late myogenic markers. CD271+ MSCs in the myogenic cell lineage transplanted into dog leukocyte antigen (DLA)-identical dogs formed clusters of muscle-like tissue. Intra-arterial injection of the CD271+ MSCs resulted in engraftment at the site of the cardiotoxin (CTX)-injured muscle. Dogs affected by X-linked muscular dystrophy in Japan (CXMDJ) treated with an intramuscular injection of CD271+ MSCs similarly developed muscle-like tissue within 8–12 weeks in the absence of immunosuppression. In the newly formed tissues, developmental myosin heavy chain (dMyHC) and dystrophin were upregulated. These findings demonstrate that a cell transplantation strategy using CD271+ MSCs may offer a promising treatment approach for patients with DMD.

21 March 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
YNYuko Nitahara-Kasahara
Yuko Nitahara-Kasahara
HHHiromi Hayashita-Kinoh
Hiromi Hayashita-Kinoh
TCTomoko Chiyo
Tomoko Chiyo
ANAkiyo Nishiyama
Akiyo Nishiyama
HOHironori Okada
Hironori Okada
TOTakashi Okada
Takashi Okada
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease that causes respiratory and cardiac failure. Inflammation is a key pathological characteristic of dystrophic muscle lesion formation, but its role and regulation in the disease time course has not been sufficiently examined. In the present study, we used IL-10−/−/mdx mice lacking both dystrophin and the anti-inflammatory cytokine, interleukin-10 (IL-10), to investigate whether a predisposition to inflammation affects the severity of DMD with advancing age. The IL-10 deficiency caused a profound DMD phenotype in the dystrophic heart such as muscle degeneration and extensive myofiber loss, but the limb muscle and diaphragm morphology of IL-10−/−/mdx mice was similar to that of mdx mice. Extensive infiltrates of pro-inflammatory M1 macrophages in regeneration of cardiotoxin-injured muscle, altered M1/M2 macrophage phenotype and increased pro-inflammatory cytokines/chemokines production were observed in the diaphragm and heart of IL-10−/−/mdx mice. We characterized the IL-10−/−/mdx mice as a dystrophic model with chronic inflammation and severe cardiorespiratory dysfunction, as evidenced by decreased percent fractional shortening (%FS) and ejection fraction percent (EF%) on echocardiography, reduced lower tidal volume on whole-body plethysmography. This study suggests that a predisposition to inflammation is an important indicator of DMD disease progression. Therefore, the development of anti-inflammatory strategies may help in slowing down the cardiorespiratory dysfunction on DMD.

15 August 2003
Verified
Journal Article
Closed access
TKTakahiro Kohno
Takahiro Kohno
HMHiroaki Mizukami
Hiroaki Mizukami
MSMitsuaki Suzuki
Mitsuaki Suzuki
YSYasushi Saga
Yasushi Saga
YTYuji Takei
Yuji Takei
KOKeiya Ozawa
Keiya Ozawa

1 March 2008 in Molecular Therapy
Verified
Journal Article
Open access
YLYuhe Liu
Yuhe Liu
TOTakashi Okada
Takashi Okada
KSKuniko Shimazaki
Kuniko Shimazaki
KSKianoush Sheykholeslami
Kianoush Sheykholeslami
TNTatsuya Nomoto
Tatsuya Nomoto
KOKeiya Ozawa
Keiya Ozawa
Since standard aminoglycoside treatment progressively causes hearing disturbance with hair cell degeneration, systemic use of the drugs is limited. Adeno-associated virus (AAV)-based vectors have been of great interest because they mediate stable transgene expression in a variety of postmitotic cells with minimal toxicity. In this study, we investigated the effects of regulated AAV1-mediated glial cell line–derived neurotrophic factor (GDNF) expression in the cochlea on aminoglycoside-induced damage. AAV1-based vectors encoding GDNF or vectors encoding GDNF with an rtTA2s-S2 Tet-on regulation system were directly microinjected into the rat cochleae through the round window at 5 × 1010 genome copies/body. Seven days after the virus injection, a dose of 333 mg/kg of kanamycin was subcutaneously given twice daily for 12 consecutive days. GDNF expression in the cochlea was confirmed and successfully modulated by the Tet-on system. Monitoring of the auditory brain stem response revealed an improvement of cochlear function after GDNF transduction over the frequencies tested. Damaged spiral ganglion cells and hair cells were significantly reduced by GDNF expression. Our results suggest that AAV1-mediated expression of GDNF using a regulated expression system in the cochlea is a promising strategy to protect the cochlea from aminoglycoside-induced damage.